Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: An implication of synergy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yue, Wen ^a   Wang, Tao ^b   Zachariah, Emmanuel ^a   Lin, Yong ^a,c   Yang, Chung S ^a,d   Xu, Qing ^e   DiPaola, Robert S ^a   Tan, Xiang Lin ^a,c  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; MESSENGER RNA; METFORMIN;

DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ASPIRIN; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; METFORMIN; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84939825859     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13390     Document Type: Article

References (59)

1. Society, A. C. Cancer Facts & Figures 2014. Atlanta: American Cancer Society (2014).
2. Yue, W., Yang, C. S., DiPaola, R. S. & Tan, X. L. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila) 7, 388-97 (2014).
3. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-74 (2001).
4. Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11, 390-401 (2010).
5. Pierotti, M. A. et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32, 1475-87 (2013).
6. Hirsch, H. A., Iliopoulos, D. & Struhl, K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 110, 972-7 (2013).
7. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69, 7507-11 (2009).
8. Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918-22 (2012).
9. Din, F. V. et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142, 1504-15 e3 (2012).
10. Alfonso, L., Ai, G., Spitale, R. C. & Bhat, G. J. Molecular targets of aspirin and cancer prevention. Br J Cancer 111, 61-7 (2014).
11. Kim, S. R. et al. Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun 387, 342-7 (2009).
12. Deng, X. S. et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11, 367-76 (2012).
13. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10, 57-63 (2009).
14. Yue, W. et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget (2015) [Epub ahead of print].
15. Dovizio, M., Bruno, A., Tacconelli, S. & Patrignani, P. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191, 39-65 (2013).
16. Lalau, J. D., Lemaire-Hurtel, A. S. & Lacroix, C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 31, 435-8 (2011).
17. Wilcock, C. & Bailey, C. J. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49-57 (1994).
18. Fantin, V. R. & Leder, P. Mitochondriotoxic compounds for cancer therapy. Oncogene 25, 4787-97 (2006).
19. Okochi-Takada, E. et al. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene 33, 2273-8 (2014).
20. Ng, K. T. et al. Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma. Mol Cancer 13, 196 (2014).
21. Mizutani, N. et al. Reduction of insulin signaling upregulates angiopoietin-like protein 4 through elevated free fatty acids in diabetic mice. Exp Clin Endocrinol Diabetes 120, 139-44 (2012).
22. Mulligan, L. M. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 14, 173-86 (2014).
23. Nair, V. et al. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 34, 2870-9 (2013).
24. Nair, V. et al. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem 289, 27692-701 (2014).
25. Schuringa, J. J. et al. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20, 5350-8 (2001).
26. Borsig, L., Wolf, M. J., Roblek, M., Lorentzen, A. & Heikenwalder, M. Inflammatory chemokines and metastasis-tracing the accessory. Oncogene 33, 3217-24 (2014).
27. Sanford, D. E. et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 19, 3404-15 (2013).
28. Baay, M., Brouwer, A., Pauwels, P., Peeters, M. & Lardon, F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol 2011, 565187 (2011).
29. Lee, H. W., Choi, H. J., Ha, S. J., Lee, K. T. & Kwon, Y. G. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta 1835, 170-9 (2013).
30. Baldwin, A. et al. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci USA 107, 12463-8 (2010).
31. Tanaka, S. et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 98, 491-8 (2006).
32. Oliveras-Ferraros, C. et al. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle 13, 1132-44 (2014).
33. Dhar, G. et al. Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymaltransition. Cancer Lett 254, 63-70 (2007).
34. Yang, Z. et al. Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer. Mol Cancer Res 13, 107-19 (2015).
35. Ma, J., Jiang, Y., Jiang, Y., Sun, Y. & Zhao, X. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol 23, 1852-9 (2008).
36. Wang, W. et al. Patterns of expression and function of the p75(NGFR) protein in pancreatic cancer cells and tumours. Eur J Surg Oncol 35, 826-32 (2009).
37. Hagihara, A. et al. Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 23, 8705-10 (2004).
38. Mori, Y. et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer 18, 465-78 (2011).
39. He, K., Jang, S. W., Joshi, J., Yoo, M. H. & Ye, K. Akt-phosphorylated PIKE-A inhibits UNC5B-induced apoptosis in cancer cell lines in a p53-dependent manner. Mol Biol Cell 22, 1943-54 (2011).
40. Liu, J., Zhang, Z., Li, Z. H. & Kong, C. Z. Clinical significance of UNC5B expression in bladder cancer. Tumour Biol 34, 2099-108 (2013).
41. Okazaki, S. et al. Clinical significance of UNC5B expression in colorectal cancer. Int J Oncol 40, 209-16 (2012).
42. Roth, G. J., Machuga, E. T. & Ozols, J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 22, 4672-5 (1983).
43. Vane, J. R. & Botting, R. M. The mechanism of action of aspirin. Thromb Res 110, 255-8 (2003).
44. Alfonso, L. F. et al. Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol 34, 597-608 (2009).
45. Marimuthu, S. et al. Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets. Int J Oncol 39, 1273-83 (2011).
46. Kamble, P., Selvarajan, K., Aluganti Narasimhulu, C., Nandave, M. & Parthasarathy, S. Aspirin may promote mitochondrial biogenesis via the production of hydrogen peroxide and the induction of Sirtuin1/PGC-1alpha genes. Eur J Pharmacol 699, 55-61 (2013).
47. Passacquale, G. et al. Aspirin-induced histone acetylation in endothelial cells enhances synthesis of the secreted isoform of netrin-1 thus inhibiting monocyte vascular infiltration. Br J Pharmacol 172, 3548-64 (2015).
48. Ibrahim Mohammed, A. M. T. Rilwanu Isah Tsamiya. Effects of acetylsalicylic acid and salicylic acid on the growth of HT3 cervical cancer cell line. American Journal of Pharmacy and Pharmacology 1, 32-44 (2014).
49. Nelson, E. R., Chang, C. Y. & McDonnell, D. P. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab 25, 649-655 (2014).
50. Gabitova, L., Gorin, A. & Astsaturov, I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20, 28-34 (2014).
51. Wu, X., Daniels, G., Lee, P. & Monaco, M. E. Lipid metabolism in prostate cancer. Am J Clin Exp Urol 2, 111-20 (2014).
52. Algire, C., Amrein, L., Zakikhani, M., Panasci, L. & Pollak, M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17, 351-60 (2010).
53. Bhalla, K. et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 5, 544-52 (2012).
54. Koren-Gluzer, M., Aviram, M. & Hayek, T. Metformin inhibits macrophage cholesterol biosynthesis rate: possible role for metformin-induced oxidative stress. Biochem Biophys Res Commun 439, 396-400 (2013).
55. Nugent, A. A., Kolpak, A. L. & Engle, E. C. Human disorders of axon guidance. Curr Opin Neurobiol 22, 837-43 (2012).
56. Mehlen, P., Delloye-Bourgeois, C. & Chedotal, A. Novel roles for Slits and netrins: axon guidance cues as anticancer targets? Nat Rev Cancer 11, 188-97 (2011).
57. Rehman, M. & Tamagnone, L. Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol 24, 179-89 (2013).
58. Gu, C. & Giraudo, E. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res 319, 1306-16 (2013).
59. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc 4, 1184-91 (2009).